Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Erasca Inc (NQ: ERAS )

1.870 +0.030 (+1.63%)
Streaming Delayed Price Updated: 11:56 AM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 145,486
Open 1.820
Bid (Size) 1.860 (14)
Ask (Size) 1.870 (18)
Prev. Close 1.840
Today's Range 1.810 - 1.870
52wk Range 1.510 - 3.100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ERAS Stock Earnings: Erasca Beats EPS for Q4 2023
ERAS stock results show that Erasca beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Erasca Announces $45 Million Oversubscribed Private Placement Financing
Funding from new and existing investors extends anticipated cash runway into H2 2026 
From Erasca, Inc.
Via GlobeNewswire

Performance

YTD
-13.82%
-13.82%
1 Month
-8.78%
-8.78%
3 Month
+2.75%
+2.75%
6 Month
-20.09%
-20.09%
1 Year
-37.56%
-37.56%

More News

Read More
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
From Erasca, Inc.
Via GlobeNewswire
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
From Erasca, Inc.
Via GlobeNewswire
Why Shares of Erasca Are Jumping Tuesday
Via The Motley Fool
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Erasca, Inc.
Via GlobeNewswire
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Erasca, Inc.
Via GlobeNewswire
3 Penny Stocks You’ll Regret Not Buying Soon: December Edition
Via InvestorPlace
RiskOn International And 3 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
From Erasca, Inc.
Via GlobeNewswire
$1.7M Bet On Erasca? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
From Erasca, Inc.
Via GlobeNewswire
Erasca Reports Third Quarter 2023 Financial Results and Business Updates
From Erasca, Inc.
Via GlobeNewswire
Erasca to Present at Upcoming Investor Conferences in November
From Erasca, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023
Via Benzinga
Erasca to Present at the Cantor Global Healthcare Conference
From Erasca, Inc.
Via GlobeNewswire
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Consolidated Water, Spectrum Brands, Arco Platform, Semler Scientific And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Erasca Reports Second Quarter 2023 Financial Results and Business Updates
From Erasca, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.